Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 29, 2015 7:37 AM ET


Company Overview of Polyphor Ltd

Company Overview

Polyphor Ltd. engages in the discovery and development of macro-cycle drugs. The company offers MacroFinder molecules, which penetrate into the cells to hit intracellular protein-protein interactions (PPI); and PEMfinder molecules that are used to address extracellular large surface PPI-targets. Its macro-cycles drugs target various therapeutic areas, such as hematopoietic stem cell transplantations, leukemia, pseudomonas infections, cystic fibrosis, alpha-1 antitrypsin deficiency, and chronic obstructive pulmonary diseases. The company was founded in 1996 and is headquartered in Allschwil, Switzerland.

Hegenheimermattweg 125

Allschwil,  4123


Founded in 1996


41 61 567 16 00


41 61 567 16 01

Key Executives for Polyphor Ltd

Chief Executive Officer
Co-Founder and Chief Scientific Officer
Co-Founder and Director
Chief Financial Officer and Head of Coporate Development
Head of Technology Platforms
Compensation as of Fiscal Year 2015.

Polyphor Ltd Key Developments

Polyphor Ltd Presents at BIO-Europe 2015, Nov-02-2015

Polyphor Ltd Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.

Polyphor and Taisho Pharmaceutical Enter into Research Collaboration on Novel Drug Candidates

Polyphor Ltd. announced the signing of a research collaboration agreement with Taisho Pharmaceutical Co., Ltd. The parties will collaborate on the identification of novel drug candidates based on Polyphor's proprietary macrocycle platform.

Polyphor Ltd. Extends Clinical Development Portfolio by Advancing its inhaled Elastase Inhibitor POL6014 for Lung Diseases to Phase I

Polyphor Ltd. announced the initiation of recruitment in a first in man clinical Phase I study with inhaled POL6014, Polyphor's proprietary macrocycle drug candidate. POL6014 is a highly selective, potent and reversible inhibitor of human neutrophil elastase (hNE), which is implicated in a number of severe respiratory diseases that frequently lead to life-threatening progressive lung deterioration as, for instance, in the orphan lung diseases Alpha-1 Antitrypsin (AAT) Deficiency and Cystic Fibrosis (CF). Inhibition of excess hNE may stop or slow lung destruction and the progressive deterioration of lung function, characteristic of many obstructive lung diseases, resulting from the proteolytic (breakdown of proteins) activity of hNE in the lung. In addition, it may also help improve lung function, exacerbation profiles and overall quality of life of patients by reducing the pro-inflammatory effect of hNE in the lung. The randomized, double-blind, placebo-controlled dose-escalation Phase I study is designed to investigate safety, tolerability and pharmacokinetics of inhaled single doses of POL6014 in healthy volunteers. The study aims to establish a safe maximum tolerated dose for future clinical studies.

Similar Private Companies By Industry

Company Name Region
Sanofi-Aventis (Suisse) SA Europe
Helvepharm AG Europe
Chemholding SA Europe
Max Zeller Söhne AG Europe
Vifor (International) AG Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Polyphor Ltd, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at